A detailed history of Man Group PLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Man Group PLC holds 408,880 shares of BPMC stock, worth $43.2 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
408,880
Previous 378,064 8.15%
Holding current value
$43.2 Million
Previous $34.9 Million 11.22%
% of portfolio
0.1%
Previous 0.1%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$73.17 - $99.79 $2.25 Million - $3.08 Million
30,816 Added 8.15%
408,880 $38.8 Million
Q4 2023

Feb 14, 2024

BUY
$43.96 - $92.84 $16.6 Million - $35.1 Million
378,064 New
378,064 $34.9 Million
Q1 2023

May 15, 2023

BUY
$37.97 - $50.0 $4.77 Million - $6.28 Million
125,582 Added 1817.13%
132,493 $5.96 Million
Q4 2022

Feb 14, 2023

SELL
$41.06 - $66.48 $1.46 Million - $2.37 Million
-35,629 Reduced 83.75%
6,911 $302,000
Q3 2022

Nov 14, 2022

BUY
$49.93 - $77.7 $2.12 Million - $3.31 Million
42,540 New
42,540 $2.8 Million
Q1 2022

May 16, 2022

SELL
$54.1 - $110.08 $2.32 Million - $4.71 Million
-42,797 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$94.25 - $115.99 $1.62 Million - $2 Million
-17,238 Reduced 28.71%
42,797 $4.58 Million
Q3 2021

Nov 15, 2021

SELL
$80.98 - $109.47 $45,186 - $61,084
-558 Reduced 0.92%
60,035 $6.17 Million
Q2 2021

Aug 16, 2021

BUY
$82.78 - $101.0 $3.8 Million - $4.63 Million
45,847 Added 310.91%
60,593 $5.33 Million
Q1 2021

May 17, 2021

SELL
$90.71 - $108.28 $4.9 Million - $5.85 Million
-54,067 Reduced 78.57%
14,746 $1.43 Million
Q4 2020

Feb 16, 2021

SELL
$92.08 - $124.48 $1.95 Million - $2.64 Million
-21,186 Reduced 23.54%
68,813 $7.72 Million
Q3 2020

Nov 16, 2020

SELL
$66.45 - $92.7 $1.48 Million - $2.06 Million
-22,233 Reduced 19.81%
89,999 $8.34 Million
Q2 2020

Aug 14, 2020

BUY
$57.09 - $79.27 $1.93 Million - $2.69 Million
33,880 Added 43.24%
112,232 $8.75 Million
Q1 2020

May 15, 2020

BUY
$48.11 - $82.22 $2.45 Million - $4.19 Million
50,915 Added 185.57%
78,352 $4.58 Million
Q4 2019

Feb 18, 2020

SELL
$66.73 - $82.59 $1.12 Million - $1.38 Million
-16,758 Reduced 37.92%
27,437 $2.2 Million
Q3 2019

Nov 14, 2019

SELL
$72.9 - $101.41 $641,592 - $892,509
-8,801 Reduced 16.61%
44,195 $3.25 Million
Q2 2019

Aug 14, 2019

BUY
$73.54 - $97.8 $3.1 Million - $4.12 Million
42,147 Added 388.49%
52,996 $5 Million
Q1 2019

May 15, 2019

BUY
$48.7 - $86.6 $210,091 - $373,592
4,314 Added 66.01%
10,849 $868,000
Q4 2018

Feb 14, 2019

SELL
$45.57 - $74.26 $563,700 - $918,596
-12,370 Reduced 65.43%
6,535 $352,000
Q3 2018

Nov 14, 2018

SELL
$58.91 - $78.32 $2.34 Million - $3.11 Million
-39,676 Reduced 67.73%
18,905 $1.48 Million
Q2 2018

Aug 14, 2018

BUY
$60.96 - $101.18 $3.57 Million - $5.93 Million
58,581 New
58,581 $3.72 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.3B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.